Pluristem Therapeutics has announced that it has agreed a strategic collaboration with Thermo Fisher to improve the process by which cell therapies are manufactured.
GE Healthcare has announced plans to install its second FlexFactory manufacturing platform for cell therapy, this time at Xiangxue Pharmaceutical’s site in Guangzhou, China.
GE Healthcare Life Sciences is expanding powdered cell culture media production in Austria and the US, where it says longer shelf-life and reduced transport costs are driving demand.
Fluid distribution and warehouse management challenges are among the ‘pitfalls’ of the single-use biopharmaceutical facility, says Avid Bioservices executive.
Berkeley Lights has signed a new agreement with Sanofi through which the company will use its Beacon OptoFluidic Platform to fast-track cell line development.
GE Healthcare Life Sciences has launched a prefabricated, modular bioprocessing facility designed for the manufacture of viral vector-based therapeutics.
A new vaccine manufacturing facility in Toronto, Canada will boast single-use tech and closed continuous process to help improve productivity and performance, Sanofi says.
Demand for a protein produced from a marine mollusk used as a carrier molecule in therapeutic vaccines has driven Stellar Biotech to expand a facility in LA.
Vendors can help address technology gaps but industry must look to collaborations and internal development to create fully continuous bioprocesses, says MilliporeSigma.
“We need Big Pharma and we are getting Big Pharma,” says Dyadic
Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.
Novartis says the manufacturing method for Regeneron’s wet macular degeneration drug Eylea (aflibercept) infringes on its Lucentis (ranibizumab) patents.
The CMO says adding the single-use offering from ABEC will make the newly opened biomanufacturing site in China comparable to stainless steel for commercial mAb production.
Egg adaptation is the biggest culprit in this year’s poor flu vaccine efficacy says Novavax, a firm developing a product based on recombinant protein nanoparticles.
Compugen has selected Selexis’ SUREtechnology cell expression platform to generate high-performance research cell banks (RCBs) and support its antibody pipeline.
The biologics CDMO will install a 2,000L single-use bioreactor (SUB) from Thermo Fisher Scientific at its Berkeley facility to meet demand for early-phase projects.
ABEC has expanded manufacturing in Ireland with the completion of an ISO-7 cleanroom, where the single-use vendor will make disposable bioreactor bags for global distribution.
The manufacturing contract is the first of what Samsung BioLogics expects to be a number of long-term partnerships at its recently completed 180,000L facility.
Repligen says the single-use version of its alternating tangential flow (ATF) platform is helping the firm capture a larger share of the fed-batch bioreactor marketplace.
“There is a new kid on the block to rival E. Coli, CHO and yeast,” says Dyadic International as it collaborates to widen the use of its C1 expression tech.
A warning letter at manufacturing partner Celltrion could delay approvals of the potential migraine prevention monoclonal antibody fremanezumab and two biosimilar candidates, says Teva.
Catalent has partially attributed a 26% year-on-year growth in its Drug Delivery Solutions segment to the acquisition of Cook Pharmica, which closed in the quarter.
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems.
Adaptimmune Therapeutics has manufactured the first SPEAR-T cells for a patient at its Navy Yard facility, which will be the primary site for its future manufacturing requirements.
Partner Therapeutics (PTx) has acquired the rights to Sanofi’s FDA-approved human growth factor Leukine along with a dedicated manufacturing plant in Washington state.
Amgen has announced plans for a US biomanufacturing facility, similar to its flexible and single-use Singapore plant, as part of $3.5bn freed through tax reforms.
The need for CDMOs with commercial gene therapy capacity is growing says Fujilfilm Diosynth Biotechnologies, which has opened an 80,000 square-foot plant in Texas.
Clover Biopharmaceuticals will adopt GE Healthcare’s centrally automated FlexFactory platform at its facility in Zhejiang, China where it plans to make a biosimilar to Amgen’s Enbrel.